scholarly journals Rho GTPase Activating Protein 24 (ARHGAP24) Regulates the Anti-Cancer Activity of Sorafenib Against Breast Cancer MDA-MB-231 Cells via the Signal Transducer and Activator of Transcription 3 (STAT3) Signaling Pathway

2018 ◽  
Vol 24 ◽  
pp. 8669-8677 ◽  
Author(s):  
Xianping Dai ◽  
Feng Geng ◽  
Jiale Dai ◽  
Mengshun Li ◽  
Ming Liu
Keyword(s):  
Breast Cancer ◽  
Signaling Pathway ◽  
Rho Gtpase ◽  
Signal Transducer ◽  
Gtpase Activating Protein ◽  
Stat3 Signaling ◽  
Stat3 Signaling Pathway ◽  
Anti Cancer ◽  
Transcription 3 ◽  
Cancer Activity

scholarly journals STAT3 pathway as a molecular target for resveratrol in breast cancer treatment

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Zeynab Kohandel ◽  
Tahereh Farkhondeh ◽  
Michael Aschner ◽  
Ali Mohammad Pourbagher-Shahri ◽  
Saeed Samarghandian
Keyword(s):  
Breast Cancer ◽  
Cancer Progression ◽  
Breast Cancer Treatment ◽  
Signal Transducer ◽  
Therapeutic Targeting ◽  
Stat3 Signaling ◽  
Naturally Occurring ◽  
Anti Cancer ◽  
Anti Oxidant ◽  
Transcription 3

AbstractSignal transducer and activator of transcription 3 (STAT3) induces breast cancer malignancy. Recent clinical and preclinical studies have demonstrated an association between overexpressed and activated STAT3 and breast cancer progression, proliferation, metastasis, and chemoresistance. Resveratrol (RES), a naturally occurring phytoalexin, has demonstrated anti-cancer activity in several disease models. Furthermore, RES has also been shown to regulate the STAT3 signaling cascade via its anti-oxidant and anti-inflammatory effects. In the present review, we describe the STAT3 cascade signaling pathway and address the therapeutic targeting of STAT3 by RES as a tool to mitigate breast cancer.

scholarly journals Erythropoietin Attenuates Experimental Contrast-Induced Nephrology: A Role for the Janus Kinase 2/Signal Transducer and Activator of Transcription 3 Signaling Pathway

2021 ◽  
Vol 8 ◽  
Author(s):  
Jia Yang ◽  
Jiaojiao Zhou ◽  
Xin Wang ◽  
Ling Ji ◽  
Siwen Wang ◽  
...  
Keyword(s):  
Signaling Pathway ◽  
Janus Kinase ◽  
Cell Counting ◽  
Signal Transducer ◽  
Janus Kinase 2 ◽  
Protein Levels ◽  
Stat3 Signaling ◽  
Stat3 Signaling Pathway ◽  
Transcription 3

The aim of the present study was to investigate the effect of erythropoietin (EPO) on contrast-induced nephrology (CIN) in vivo and in vitro. Male C57BL/6J mice were divided into four groups: control, CIN (iohexol 6.0 g/kg), EPO (3,000 IU/kg), and CIN+EPO. Hematoxylin and eosin (H&E) staining and biochemical index analyses were performed to evaluate renal injury. The cellular proliferation rate was detected using the Cell Counting Kit-8 (CCK-8) assay. In addition, a terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay and flow cytometric assay were used to assess the apoptosis of tissue and cells, respectively. Renal protein expression associated with apoptosis, pyroptosis, and signaling pathways was determined by Western blot (WB) assays for tissues and cells. The results showed that EPO significantly decreased serum creatinine, blood urea nitrogen, and cystatin C levels and alleviated renal histological changes in vivo. The protein levels of Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway components were overexpressed in the EPO treatment group. Furthermore, EPO suppressed the cell apoptosis and pyroptosis; decreased the protein levels of cleaved caspase-3, Bax, gasdermin D (GSDMD), and caspase-1; and enhanced the expression of Bcl-2. In summary, EPO could exert renoprotective effect by activating the JAK2/STAT3 signaling pathway, which may be a novel potential therapy for the treatment of CIN in the clinic.

Sign in / Sign up

Export Citation Format

Share Document